SL Science Holding Ltd (SLBT) Form 6-K — Oct 26, 2026
SL Science Holding, the Cayman parent formed to take Taiwan biotech SL Bio public through a reverse merger with SPAC Horizon Space Acquisition II Corp, reported its first interim results as a Nasdaq-listed company (SLBT) following the June 12, 2026 business combination closing and June 15 listing. For the six months ended June 30, 2026, revenue rose 22.8% year-over-year to $1.39 million, driven by exosome concentrate wholesale sales in Taiwan, while gross margin improved to 40.2% from 34.5%. However, the net loss widened to $2.16 million from $1.60 million as R&D spending jumped 71.5% on CD-19 Armed-T and GDT cell therapy programs.
Key figures
- Eps
- 0
- Revenue
- 1386608
- Revenue Yoy
- 22.8%
- Cash Position
- 8306692
- Gross Proceeds
- 7800000
- Shares Outstanding
- 560759740
- Pipe units
- 780000
- Working capital
- 6700000
- Gross margin 2025
- 34.5%
- Gross margin 2026
- 40.2%
- Accumulated deficit
- 7646583
- Pipe price per unit
- 10
- Weighted avg shares
- 557215664
- Prior period revenue
- 1129238
- Jy biomed paid to date
- 1000000
- Net cash from financing
- 9151301
- Cytoarm remaining consideration
- 4096400
- Jy biomed license total consideration
- 38000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.